Journament

Keyword Connections - EGFR Keywords

Connection Type	Connection
Journals	European journal of medicinal chemistry Bioorganic chemistry International journal of pharmaceutics PeerJ Bioorganic & medicinal chemistry letters molecular biology reports Journal of biomolecular structure & dynamics Journal of medical virology International wound journal journal of materials chemistry b Travel medicine and infectious disease the international journal of oral & maxillofacial implants molecular and cellular biology current problems in cancer The Lancet. Respiratory medicine
Research Groups	No Research Group Connected
Bibliographies	[1] The heart of a hibernator: EGFR and MAPK signaling in cardiac muscle during the hibernation of thirteen-lined ground squirrels, . [2] Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors. [3] Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. [4] pH-Responsive polyelectrolyte coated gadolinium oxide-doped mesoporous silica nanoparticles (GdO@MSNs) for synergistic drug delivery and magnetic resonance imaging enhancement. [5] Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study. [6] EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling. [7] Immediate Dental Implant Stabilization in a Canine Model Using a Novel Mineral-Organic Adhesive: 4-Month Results. [8] synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting egfr [9] a pilot study (swog s0429) of weekly cetuximab and chest radiotherapy for poor-risk stage iii non-small cell lung cancer [10] survival predictors in paraquat intoxification and role of immunosuppression [11] thyroid dysfunctions and renal status: implications in hyponatremia [12] association between cd47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer [13] role of the expression level of nrf2 in predicting response of egfr-tkis  in lung adenocarcinoma patients with egfr gene mutations [14] identification and characterization of egf receptor in individual exosomes by fluorescence-activated vesicle sorting [15] reversing egfr mediated immunoescape by targeted monoclonal antibody therapy [16] the association of daily activity levels and estimated kidney function in men and women with predialysis chronic kidney disease [17] universal insertion/deletion-enrich pcr [18] non-small cell carcinoma biomarker testing: the pathologist's perspective. [19] induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice [20] new developments in the treatment of advanced squamous cell lung cancer: focus on afatinib [21] folliculin interacts with rab35 to regulate egf-induced egfr degradation [22] response to her2 inhibition in a patient with brain metastasis with egfr tki acquired resistance and an her2 amplification [23] estimated glomerular filtration rate (egfr): a serum creatinine-based test for the detection of chronic kidney disease and its impact on clinical practice [24] an immunohistochemical study of egfr expression in colorectal cancer and its correlation with lymph nodes status and tumor grade [25] mechanisms of activation of receptor tyrosine kinases: monomers or dimers [26] Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. [27] Omicron N501Y mutation among SARS-CoV-2 lineages: In-silico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine. [28] Omicron variant and booster COVID-19 vaccines. [29] Another year another variant: COVID 3.0-Omicron. [30] SARS-CoV-2 Omicron Variant: Could it be Another Threat? [31] Exploring the potential of biologically active phenolic acids from marine natural products as anticancer agents targeting the epidermal growth factor receptor. [32] Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR. [33] Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors. [34] Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. [35] Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. [36] Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. [37] EGFR signaling in colorectal cancer: a clinical perspective [38] EGFR signaling in colorectal cancer: a clinical perspective [39] EGFR signaling in colorectal cancer: a clinical perspective [40] New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors. [41] Synthesis and preclinical investigation of Tc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts. [42] Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model. [43] KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program [44] Interleukin 1 beta and Matrix Metallopeptidase 3 Contribute to Development of EGFR-dependent Serrated Polyps in Mouse Cecum. [45] Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway. [46] EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer. [47] Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. [48] Correction: Kaempferol inhibits angiogenesis by suppressing hif-1α and vegfr2 activation via erk/p38 mapk and pi3k/akt/mtor signaling pathways in endothelial cells (Preventive Nutrition and Food Science (2017) 22: 4 (320-326) [49] Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer. [50] Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas. [51] Decreased eGFR Is Associated With Ischemic Stroke in Patients With Dilated Cardiomyopathy. [52] Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation. [53] The heart of a hibernator: EGFR and MAPK signaling in cardiac muscle during the hibernation of thirteen-lined ground squirrels, . [54] Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors [55] Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent [56] Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities. [57] Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors. [58] Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1,2,3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents [59] ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors. [60] EGFR signaling promotes β-cell proliferation and survivin expression during pregnancy. [61] Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. [62] Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. [63] Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma. [64] Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m and negative proteinuria. [65] Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA. [66] Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. [67] Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. [68] Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway [69] Vascular Endothelial Growth Factor A and VEGFR-1 Change during Preimplantation in Heifers. [70] Corrigendum to ‘Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2’ [European journal of medicinal chemistry 158 (2018) 814–831](S0223523418308225)(10.1016/j.ejmech.2018.09.050) [71] Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. [72] Prospective pediatric study comparing glomerular filtration rate estimates based on motion-robust dynamic contrast-enhanced magnetic resonance imaging and serum creatinine (eGFR) to Tc DTPA. [73] Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity. [74] Correction to: EGFR signaling augments TLR4 cell surface expression and function in macrophages via regulation of Rab5a activation. [75] Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDH wt astrocytoma to glioblastoma [76] a high expression egfr/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening egfr antagonists from rhizoma polygoni cuspidati [77] quantitative analysis of [11c]-erlotinib pet demonstrates specific binding for activating mutations of the egfr kinase domain [78] severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring egfr mutation [79] serum zag levels were associated with egfr mild decrease in t2dm patients with diabetic nephropathy [80] synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting egfr [81] tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report [82] egfr protein expression using a specific intracellular domain antibody and pten and clinical outcomes in squamous cell lung cancer patients with egfr-tyrosine kinase inhibitor therapy [83] tgf-β and hypoxia/reoxygenation promote radioresistance of a549 lung cancer cells through activation of nrf2 and egfr [84] vascular endothelial growth factor and its soluble receptors vegfr-1 and vegfr-2 in the serum of patients with systemic lupus erythematosus [85] formyl peptide receptor 1 modulates endothelial cell functions by nadph oxidase-dependent vegfr2 transactivation [86] mir-sc8 inhibits schwann cell proliferation and migration by targeting egfr. [87] spectrum of egfr gene copy number changes and kras gene mutation status in korean triple negative breast cancer patients. [88] chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients [89] role of the expression level of nrf2 in predicting response of egfr-tkis  in lung adenocarcinoma patients with egfr gene mutations [90] quantum dots immunofluorescence histochemical detection of egfr gene mutations in the non-small cell lung cancers using mutation-specific antibodies [91] reversing egfr mediated immunoescape by targeted monoclonal antibody therapy [92] expressions of c-cbl, cbl-b and egfr and its role of prognosis in nsclc [93] siegfried j. schmidt: kalte faszination. medien-kultur-wissenschaft [94] the immune system's contribution to the clinical efficacy of egfr antagonist treatment [95] the involvement of kras gene 3'-utr polymorphisms in risk of cancer and influence on patient response to anti-egfr therapy in metastatic colorectal cancer: a meta-analysis [96] clinical analysis of icotinib on beneficiary of  advanced non-small cell lung cancer with egfr common mutation [97] expression of egfrviii in glioblastoma: prognostic significance revisited [98] folliculin interacts with rab35 to regulate egf-induced egfr degradation [99] egfr-targeted delivery of dox-loaded fe3o4@polydopamine multifunctional nanocomposites for mri and antitumor chemo-photothermal therapy [100] response to her2 inhibition in a patient with brain metastasis with egfr tki acquired resistance and an her2 amplification [101] estimated glomerular filtration rate (egfr): a serum creatinine-based test for the detection of chronic kidney disease and its impact on clinical practice